高致病性蓝耳病纯化灭活疫苗的研制(英文)

目的]改进和提高现行高致病性蓝耳病(HR-PRRS)灭活疫苗的纯度和效价。方法]该研究将经Marc-145细胞培养收获的HP-PRRS病毒原液超滤浓缩50倍,灭活后用Sepharose 4 Fast Flow分子筛柱层析,收集完整的病毒粒子,加油佐剂制成纯化HP-PRRS灭活疫苗。结果]通过纯化可将HP-PRRS病毒与非病毒蛋白分开,纯化后测定病毒蛋白含量收率为76.7%~82.4%,杂蛋白含量去除率均为96%以上,且纯化疫苗的攻毒保护率达到4/5以上,血清抗体检测阳转率达86%以上,均高于未纯化灭活疫苗,差异显著。结论]HR-PRRS病毒液经浓缩纯化制成疫苗后,增强了免疫效果,并可有效地去除杂蛋白,避免了疫苗的过敏反应和应激反应。

Preparation of Purified and Inactivated HP-PRRS Vaccine

Objective] The aim of this study was to improve the purification and protective potency of HP-PRRS inactivated vaccine. Method] HP-PRRS virus that had been multiplied inside Marc-145 cells was collected and concentrated 50 times and then inactivated. Complete virions were separated and collected by chromatography with Sepharose 4 Fast Flow. Oil adjuvant was added to prepare purified inactivated vaccine. Result] Viral protein was separated from other proteins by purification and the viral protein contents ranged from 76.7% to 82.4%, and 96% of the expected serum proteins were removed. Protective potency of purified vaccine was above 4/5 and positive conversion rate of antibody was over 86%, both higher than that of unpurified vaccine. The differences were significant. Conclusion] The experiment il-lustrated that the immune efficacy of vaccine can be enhanced through concentrat- ing and purifying, while the non-viral protein can be removed, so that allergic reaction and stress response cadsed by vaccine inoculation can be avoided.